IL100332A0 - Oral administration of alpha interferon to treat lung malignancies - Google Patents

Oral administration of alpha interferon to treat lung malignancies

Info

Publication number
IL100332A0
IL100332A0 IL100332A IL10033291A IL100332A0 IL 100332 A0 IL100332 A0 IL 100332A0 IL 100332 A IL100332 A IL 100332A IL 10033291 A IL10033291 A IL 10033291A IL 100332 A0 IL100332 A0 IL 100332A0
Authority
IL
Israel
Prior art keywords
oral administration
alpha interferon
treat lung
lung malignancies
malignancies
Prior art date
Application number
IL100332A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of IL100332A0 publication Critical patent/IL100332A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL100332A 1990-12-14 1991-12-11 Oral administration of alpha interferon to treat lung malignancies IL100332A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62824090A 1990-12-14 1990-12-14

Publications (1)

Publication Number Publication Date
IL100332A0 true IL100332A0 (en) 1992-09-06

Family

ID=24518070

Family Applications (1)

Application Number Title Priority Date Filing Date
IL100332A IL100332A0 (en) 1990-12-14 1991-12-11 Oral administration of alpha interferon to treat lung malignancies

Country Status (11)

Country Link
EP (1) EP0563177A1 (xx)
JP (1) JPH06503570A (xx)
AU (1) AU9139091A (xx)
CA (1) CA2098393A1 (xx)
EE (1) EE9400337A (xx)
IE (1) IE914326A1 (xx)
IL (1) IL100332A0 (xx)
MX (1) MX9102512A (xx)
PT (1) PT99784A (xx)
WO (1) WO1992010207A1 (xx)
ZA (1) ZA919769B (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9213322D0 (en) * 1992-06-23 1992-08-05 Efamol Holdings Antioxidant compositions
ES2161793T3 (es) * 1994-04-09 2001-12-16 Hoffmann La Roche Proceso para la produccion de alfa-interferona.
US6207145B1 (en) 1997-05-09 2001-03-27 Pharma Pacific Pty Ltd. Therapeutic applications of high dose interferon
AUPN976596A0 (en) * 1996-05-09 1996-05-30 Pharma Pacific Pty Ltd Stimulation of host defence mechanisms
CN1151840C (zh) * 1996-05-09 2004-06-02 太平洋制药控股公司 干扰素在制备用于治疗哺乳动物肿瘤病的药剂中的应用
JP3806445B2 (ja) 1996-05-09 2006-08-09 ファーマ・パシフィック・プロプライエタリー・リミテッド 治療方法
US6660258B1 (en) 1997-05-09 2003-12-09 Pharma Pacific Pty Ltd Oromucosal cytokine compositions and uses thereof
AU2002330801A1 (en) * 2002-06-20 2004-01-06 Igor Anatolievich Pomytkin Method for oral transmucosal delivery of interferon

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0077063B1 (en) * 1981-10-13 1988-03-16 Exovir, Inc. Interferon-containing compositions and the use of these compositions in the treatment of herpetic infections, pre-malignant skin lesions, skin malignancies and psoriasis
EP0372809B1 (en) * 1988-12-01 1993-08-04 Schering Corporation Medicament for the treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon

Also Published As

Publication number Publication date
EP0563177A1 (en) 1993-10-06
ZA919769B (en) 1992-09-30
MX9102512A (es) 1992-06-01
IE914326A1 (en) 1992-06-17
AU9139091A (en) 1992-07-08
CA2098393A1 (en) 1992-06-15
PT99784A (pt) 1992-12-31
WO1992010207A1 (en) 1992-06-25
EE9400337A (et) 1996-02-15
JPH06503570A (ja) 1994-04-21

Similar Documents

Publication Publication Date Title
GB2231265B (en) Therapeutic use of serotonin-antagonists
GB8618466D0 (en) Administering medicaments to patients
PH30282A (en) Use of purified surface modifiers to prevent particle aggregation during sterilization
PH22677A (en) Treatment of oral diseases
GB8326878D0 (en) Administering medicaments to patients
GB8602264D0 (en) Administering medicaments to patients
EP0202051A3 (en) Therapeutic compositions for oral administration
EP0436653A4 (en) Synthesis of camptothecin and analogs thereof
GB2176584B (en) Improvements relating to the treatment of tobacco
IL100332A0 (en) Oral administration of alpha interferon to treat lung malignancies
EP0249165A3 (en) Medicine for combating malignant and chronic diseases
GB9122609D0 (en) Improvements relating to the treatment of haemophilia
HU9301453D0 (en) Nucleinic acide derivatives of anesthetic effect
ZW5790A1 (en) Interferon for the use in the prevention or treatment of swine pneumonia or related bacterial diseases
IL100415A0 (en) Administering alpha interferon by oral inhalation to treat asthma and non-malignant proliferative pulmonary diseases
ZA919959B (en) Administering alpha interferon by oral inhalation to treat asthma and non-malignant proliferative pulmonary diseases
AU609435B2 (en) Prevention of bovine respiratory disease complex in cattle by administration of interferon
IT9021051A0 (it) "procedimento di estrzione e purificazione del gamma interferone umano ricombite"
GB9026620D0 (en) Treatment of lung diseases
ZA879325B (en) Prevention of bovine respiratory disease complex in cattle by administration of interferon
GB8519141D0 (en) Administering medicaments to patients
IE861386L (en) Treatment of oral diseases
GB8813119D0 (en) Administration of vaccines to fish
IL80048A0 (en) Mouthpiece for preventing intake of smoke
ZA875652B (en) Therapeutic use of serotonin-antagonists